HC Wainwright Reiterates Buy Rating on Elicio Therapeutics
HC Wainwright maintains its buy rating for Elicio Therapeutics with a $23 price target, a 388.32% upside from the current price.
Key Points
- HC Wainwright reiterated its buy rating on Elicio Therapeutics, maintaining a $23 price target as of June 15, 2026.
- HC Wainwright's $23 price target implies 388.32% upside from Elicio Therapeutics, Inc.'s ($ELTX) current $4.71 share price.
- Elicio Therapeutics, trading at $14.85, has a market cap of $283 million and a 52-week range between $7.37 and $16.00.
- Vanguard Capital Management added 518,638 shares of Elicio, while Balyasny Asset Management increased its stake by 106,052 shares.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
HC Wainwright & Co. reiterated its buy rating for Elicio Therapeutics, Inc. (NasdaqCM: ELTX) on June 15, 2026, maintaining a price target of $23. This reflects confidence in the biotechnology firm's prospects, as shares currently trade at $14.85.
Other Institutional Activity in Elicio Therapeutics
Notable institutional activity includes Vanguard Capital Management, which added 518,638 shares, bringing its total to 518,638 shares valued at approximately $5.54 million. Balyasny Asset Management increased its holdings by 106,052 shares, resulting in a total of 244,814 shares worth about $2.62 million. Meanwhile, Geode Capital Management modestly grew its stake by 2,646 shares, ending with 135,164 shares valued at $1.45 million. Renaissance Technologies significantly boosted its position by 93,520 shares, totaling 121,631 shares valued at $1.3 million.
Elicio Therapeutics, Inc. Stock Up 65.8%
Shares of Elicio Therapeutics are trading near $14.85. The company has a market capitalization of approximately $283 million. Although it is not yet profitable, its forward P/E ratio is not meaningful. The stock's 52-week range is between $7.37 and $16.00, with a 50-day moving average of $11.37 and a 200-day moving average of $10.07. Elicio has a current ratio of 2.24 and a quick ratio of 2.07, reflecting solid liquidity.
Insider Buying and Selling at Elicio Therapeutics, Inc.
On February 2, 2026, several executives at Elicio Therapeutics made notable stock purchases. CEO Robert Connelly acquired 147,200 shares, while Chief Scientific Officer Peter Demuth and Chief Strategy and Financial Officer Preetam Shah bought 41,600 and 47,900 shares, respectively. Executive Vice President Christopher Haqq also purchased 25,400 shares. These transactions were not part of a pre-planned trading program.
Analysts Set New Price Targets
On June 15, 2026, HC Wainwright maintained its buy rating for Elicio Therapeutics with a $23 price target. Earlier, on June 10, 2026, B. Riley Securities initiated coverage with a buy rating and a $27 target. Ladenburg Thalmann also initiated coverage on April 15, 2026, with a buy rating and a $20 target. The consensus among analysts is a strong buy, with an average target price of $20.67 based on three opinions.
About Elicio Therapeutics
Elicio Therapeutics, Inc., based in Boston, Massachusetts, is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment. Its lead product, ELI-002, is a vaccine targeting specific cancer mutations, currently in Phase II trials. The company is also working on ELI-007 and ELI-008, targeting other cancer mutations. Elicio is led by CEO Robert T. Connelly and employs 33 people.
Bottom Line
HC Wainwright's reiterated buy rating and $23 target price signal continued confidence in Elicio Therapeutics' potential. Investors track such ratings to gauge market sentiment, though these are backward-looking and may not reflect current conditions. With its focus on innovative cancer treatments, Elicio remains a company to watch in the biotechnology sector.
Get Elicio Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $ELTX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.